Gilead-Kite Yescarta 1st CAR T-cell Therapy to Get Euro OK for Use in Second-Line Lymphomas

 -- First Treatment in 30 Years to Improve Upon Standard of Care (SOC) for Second-Line Treatment of DLBCL –

-- Based on Landmark ZUMA-7 Study, Patients with DLBCL Treated Second-Line with Yescarta Had Event-Free Survival of 8.3 Months versus Two Months for SOC [4-fold greater improvement] --

-- In ZUMA-7, Yescarta Patients with DLBCL were 2.5 Times More Likely than SOC to be Alive at Two Years Without Cancer Progression or Need for Additional Treatments --

https://finance.yahoo.com/news/kite-yescarta-first-car-t-203000030.html